Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy
- 1 May 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2100344
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian CarcinomaPLOS ONE, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Metformin, an Antidiabetic Agent Reduces Growth of Cutaneous Squamous Cell Carcinoma by Targeting mTOR Signaling Pathway†Photochemistry and Photobiology, 2012
- Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancerBMC Cancer, 2012
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic ProfilingJournal of Clinical Oncology, 2011
- Activation of the PI3K/AKT signalling pathway in non‐melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutationsExperimental Dermatology, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Mutations induced by ultraviolet lightMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2001